J&J plans to split into two public companies and separate consumer and drug businesses


Johnson & Johnson shares JNJ, +1.20% jumped 3.6% in premarket trade Friday, after Chief Executive Alex Gorksy told the Wall Street Journal that the company plans to split into two companies, splitting off the consumer group from the prescription drugs and medical devices business. The company confirmed the story in a release early Friday. J&J will separate the consumer business in 18 to 24 months, he said, because its customers and markets have diverged so much from the rest of the business in recent years, including during the pandemic. “The best path forward to ensure sustainable growth over the long term and better meet patient and consumer demands is to have our consumer business operate as a separate healthcare company,” Mr. Gorsky said in an interview. The company intends to conduct the separation on a tax-free basis, although details have yet to be worked out, said Gorsky. Pfizer Inc. PFE, -0.90% and Merck MRK, -0.02% have also decided to split their consumer and drug businesses, and earlier this week, General Electric Co. GE, +0.55% announced a plan to break into three public companies. J&J shares have gained 3.6% in the year through Thursday, while the Dow Jones Industrial Average DJIA, +0.50% has gained 17% and the S&P 500 SPX, +0.72% has gained 24%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleBrett Arends’s ROI: Your diet isn’t just making you obese, it could be speeding up cognitive decline
Next articleProject Syndicate: The culprit for high inflation? Too much efficiency


Please enter your comment!
Please enter your name here